Highmark Inc. Announces Outcomes-Based Agreement with Boehringer Ingelheim for Jardiance® | Blue Cross Blue Shield

Highmark Inc. Announces Outcomes-Based Agreement with Boehringer Ingelheim for Jardiance®

Subtitle
Jardiance (empagliflozin) Agreement Marks Highmark’s Second Outcomes-Based Contract this Year

PITTSBURGH, Pa (July 10, 2018) – Continuing its efforts to address high prescription drug costs, Highmark Inc. today announced its latest outcomes-based contract with Boehringer Ingelheim for Jardiance® (empagliflozin), an oral medicine indicated to lower blood sugar in adults with type 2 diabetes, and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease. Jardiance is a product in the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance portfolio. 

The contract focuses on an analysis of the total cost of care for adults with type 2 diabetes and established cardiovascular disease who have been prescribed Jardiance, compared with people who have not been prescribed Jardiance. This analysis is important given that cardiovascular disease is the leading cause of disability and death for people with diabetes. 

“We’re committed to prioritizing contract agreements which drive members to clinically-effective treatments while also managing the cost of care,” said Ryan Cox, RPh., director of specialty pharmacy strategies at Highmark Inc. “It’s estimated that health care costs for Americans with diabetes are more than two times greater than those without diabetes, and we continue to see significant costs across our type 2 diabetes membership base.” 

Applicable to commercial members in Highmark’s national and core health insurance markets in Pennsylvania, West Virginia and Delaware, the agreement’s objective is to compare actual per member, per month medical and pharmacy costs of Jardiance – along with other oral fixed-dose treatments containing empagliflozin, including Synjardy® (empagliflozin and metformin hydrochloride), Synjardy® XR (empagliflozin and metformin hydrochloride extended-release) or Glyxambi® (empagliflozin/linagliptin) – with the medical and pharmacy costs of all other antidiabetic medications.

“The fundamental goal in this contract is to improve outcomes for our members. In an ideal scenario, Highmark would not see any additional financial savings because Jardiance is performing as we anticipated,” said Kayse Reitmeyer, Pharmaceutical Manufacturer Relations Director, Highmark Inc. “By negotiating value-based contracts like this one, we’re building structures that facilitate payment for quality of care over quantity or volume of care.”

Following the one-year contract period, Highmark will review aggregated dollar amounts of corresponding claims and compare those to members not on Jardiance or any other fixed-dose oral treatments containing empagliflozin. As a result, Highmark may realize minimal savings, which would be dependent on the extracted data. 

“We’re excited to enter into this outcome-based contract with Highmark to continue our work in improving outcomes for people with diabetes who are at an increased risk for cardiovascular disease,” said Christine Marsh, vice president, Market Access, Boehringer Ingelheim Pharmaceuticals, Inc. “Our value-based contracts reflect our confidence in Jardiance to help reduce overall healthcare costs for this community and further our commitment to ensuring Jardiance is accessible to the people who need it.”

This announcement marks the second outcomes-based contract between Highmark Inc. and a pharmaceutical company.

“There’s a national conversation taking place around the increasing costs of pharmaceutical prices for patients, and Highmark is determined to innovate for progressive contracts and agreements which lessen the total burden for those prescribed,” continued Cox. “We take being a partner in health care seriously and this agreement is another step in the right direction as we continue to focus on health care experiences founded in quality and affordability.”

About Highmark Inc. 
Highmark Inc. and its health insurance subsidiaries and affiliates collectively are one of America’s largest health insurance organizations and together with its Blue-branded affiliates, collectively comprise the third-largest overall Blue Cross and Blue Shield-affiliated organization in the country based on capital. Highmark Inc. and its affiliates operate health insurance plans in Pennsylvania, Delaware and West Virginia that serve approximately 4.6 million members and hundreds of thousands of additional individuals through the BlueCard® program. Its diversified businesses serve group customer and individual needs across the United States through dental insurance, vision care and other related businesses. Highmark Inc. is an independent licensee of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield companies. For more information, visit www.highmark.com.

About Blue Cross Blue Shield Association

The Blue Cross and Blue Shield Association is a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield companies that collectively provide health care coverage for one in three Americans. BCBSA provides health care insights through The Health of America Report series and the national BCBS Health Indexsm. For more information on BCBSA and its member companies, please visit BCBS.com. We also encourage you to connect with us on Facebook, check out our videos on YouTube and follow us on Twitter.

The Blue Cross Blue Shield Association is an association of 36 independent, locally operated Blue Cross and/or Blue Shield companies.